GW suffers major blow as US sinks bid to patent cannabinoids for epilepsy

British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The US Patent Trial and Appeal Board, an administrative law body of the national patent office, denied patent US9066920B2 on January 3, siding with petitioner Insys, a rival biotech firm.

Continue Reading →

EU drug agency releases key report as lawmakers commit to cannabis study

Health committee politicians in the European Parliament, the EU’s directly elected legislative, voted in late 2018 to approve a draft resolution on the use of cannabis for medicinal purposes, and now the proposals will head to the bloc’s executive to be turned into a concrete proposal.

Continue Reading →